BioPharma Credit : Notice of AGM

BioPharma Credit plc

(the 'Company')

NOTICE OF ANNUAL GENERAL MEETING

Following the publication on 10 March 2020 of its Annual Financial Report for the year ended 31 December 2019, the Company announces that it will hold its Annual General Meeting ('AGM') at 2.00 p.m. on 25 June 2020 at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG.

As a result of the ongoing Coronavirus pandemic and the current prohibition on public gatherings, members will not be permitted to attend the AGM and ask questions in person. Shareholders who wish to ask questions may do so by contacting the Company Secretary at [e-mail]. These questions will be answered on a conference call on 26 June 2020 at 2.00 p.m. Shareholders who wish to make use of this facility may do so by [e-mail].

As noted in the Notice of the AGM, although the Chairman, Mr Sillem, will be seeking re-election at the upcoming AGM, it is currently intended that he will retire as a Director of the Company in the course of the year and be replaced as Chairman by Mr Hyman, who is currently Senior Independent Director of the Company. The effective date of Mr Sillem's departure has not yet been determined and the Company will announce that date in due course.

A copy of the Notice of the AGM is available to view on the Company's website at http://www.bpcruk.com. It has also been submitted to the National Storage Mechanism and will shortly be available for inspection athttps://data.fca.org.uk/#/nsm/nationalstoragemechanism. Copies of the Notice of the AGM, together with a form of proxy for use in connection with the AGM, are being posted or made available to the Company's Shareholders today.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

[phone]

Buchanan

[phone] / [e-mail]

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24